$ADIL
Azora Therapeutics, Inc. (DE)
Nasdaq · Healthcare · Pharmaceutical Preparations · Encino, CA
ADIL chart
What traders are saying about $ADIL
Latest postsAzora Therapeutics, Inc. (DE) news
- Azora Therapeutics Appoints Board of Directors with Extensive Drug Development and Inflammatory Bowel Disease Expertise
Yahoo Finance ·
- Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
Yahoo Finance ·
- Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
Yahoo Finance ·
- Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis
Yahoo Finance ·
- Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
Yahoo Finance ·
- Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
Yahoo Finance ·
- Sector Update: Healthcare Stocks Higher Late Afternoon
Yahoo Finance ·
- ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally
stocktwits.com ·
- Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
Yahoo Finance ·
- Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight
Yahoo Finance ·
- Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
Yahoo Finance ·
Azora Therapeutics, Inc. (DE) key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$7.98T | -$13.20T | -$5.12T | -$12.7M |
| Diluted EPS | $-11.93 | $-68.01 | $-3.60 | $-12.71 |
| Total assets (year end) | $6.7M | $5.0M | $4.7M | $5.7M |
| Cash and equivalents (year end) | $5.9M | $3.8M | $2.8M | $4.0M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Azora Therapeutics, Inc. (DE)
- Ticker
- ADIL (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Encino, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1513525
- Former names
- ADIAL PHARMACEUTICALS, INC., Adial Pharmaceuticals, L.L.C., ADial Pharmaceuticals, L.L.C.
Frequently asked questions
What exchange is Azora Therapeutics, Inc. (DE) listed on?
Azora Therapeutics, Inc. (DE) trades on the Nasdaq under the ticker symbol ADIL.
What industry is Azora Therapeutics, Inc. (DE) in?
Azora Therapeutics, Inc. (DE) is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Azora Therapeutics, Inc. (DE) headquartered?
Azora Therapeutics, Inc. (DE)'s business address on file with the SEC is in Encino, CA.
When does Azora Therapeutics, Inc. (DE)'s fiscal year end?
Azora Therapeutics, Inc. (DE)'s fiscal year ends on December 31.